
    
      The purpose of this observational study is to give an overview of the use of PASCOE-Agil
      HOM-Injektopas in a 2-4 week treatment of rheumatic disorders of different aetiology and
      localisation, displaying a variety of symptoms.

      Efficacy and tolerability of the drug will be assessed. Special regard will be taken to the
      administration management in relation to the Summary of Product Characteristics (SmPC).
    
  